Applied Genetic Technologies Corporation
Applied Genetic Technologies Corporation company was formed in 1999; funding partners include InterWest Partners, InterSouth Partners, and MedImmune Ventures. Applied Genetic Technologies Corporation (AGTC) applies itself to developing gene therapies for acquired and inherited genetic diseases. Its lead product is a treatment for Alpha One Antitrypsin Deficiency, which is an inherited cause of emphysema that is the most common hereditary disease in the Western World. Aside from causing lung disease in adults, it can also lead to liver disease in children. AGTC is also developing a treatment for Leber Congenital Amaurosis, which causes blindness, in collaboration with the universities of Florida and Pennsylvania, and Cornell University.
Contact Details
Office Address
Applied Genetic Technologies Corporation
11801 Research Drive, Suite D
Alachua, FL, USA 32615
Phone: (386) 462-2204
Fax: (386) 462-0875
Executives
President, CEO, and Director
Sue Washer
Director Finance
Teresa Heal